Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – A large increase in the number of lymph nodes evaluated during surgery for colon cancer — a quality improvement metric– has not had…
NEW YORK (Reuters Health) – Patients undergoing surgery for spinal metastases at teaching hospitals in July have higher mortality and complication rates than similar patients treated in other…
NEW YORK (Reuters Health) – Endoscopic ablation of Barrett’s esophagus can bury metaplastic glands under a layer of neosquamousepithelium. However, how often this happens and its importance still…
NEW YORK (Reuters Health) – Patients with prostate cancer involving the seminal vesicle and who undergo radical prostatectomy fare best when given adjuvant radiotherapy plus androgen deprivation therapy,…
NEW YORK (Reuters Health) – New data from phase III randomized clinical trials have prompted a focused update of one recommendation contained in the 2009 American Society of…
NEW YORK (Reuters Health) – A Canadian guideline on ovarian ablation in premenopausal women with breast cancer has been endorsed by the American Society of Clinical Oncology (ASCO),…
NEW YORK (Reuters Health) – An analysis of epidemiologic data confirms that the incidence of second primary malignancies is increased after external beam radiotherapy (EBRT) for stage I…
NEW YORK (Reuters Health) – Dexamethasone may be a useful supplement to standard treatment of certain patients with acute monocytic leukemia, French researchers report in an August 4th…
NEW YORK (Reuters Health) – Surgery offers the best hope for survival in patients with the rare intracranial hemangiopericytoma (HPC), researchers from San Francisco report in the August…
NEW YORK (Reuters Health) – The combination of epirubicin and ifosfamide is effective in patients with relapsed or refractory small cell lung cancer (SCLC), researchers from France report…
